Search Results
Your search for ,had matches 18486 pages
Showing 6051 - 6100High- vs Standard-Dose Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer
In a phase II trial reported in The Lancet Oncology, Grønberg et al found that use of high-dose vs standard-dose twice daily thoracic radiotherapy as part of first-line chemoradiotherapy was associated with significantly improved overall survival and similar toxicity in patients with limited-stage...
Study Finds Regularly Drinking Sugar-Sweetened Soda May Increase Total and Breast Cancer Mortality
New research published by Koyratty et al in Cancer Epidemiology, Biomarkers & Prevention suggests that patients with breast cancer who drink sugar-sweetened beverages regularly are at increased risk for death from any cause, and from breast cancer in particular. Compared to women who never or...
Expect Questions From Older Breast Cancer Survivors About Discontinuing Routine Surveillance Mammography
Consensus guidelines recommending that routine surveillance mammography be discontinued for older breast cancer survivors with a limited life expectancy1 may raise questions among patients concerned about undetected cancer recurrence. Informing older survivors about the new recommendations and the...
Older Breast Cancer Survivors May Consider Discontinuing Screening Mammography in the Setting of Limited Life Expectancy
Newly issued mammography screening guidelines for breast cancer survivors aged 75 and older recommend discontinuing routine mammography for those with a life expectancy of less than 5 years and considering discontinuation of routine screening for those with a life expectancy between 5 and 10 years. ...
New Survey Reveals Hesitancy Around COVID-19 Vaccination Among Patients With Hematologic Malignancies and Survivors
A survey of more than 6,500 U.S. patients with blood cancer and survivors revealed that only half are very likely to get a COVID-19 vaccine, while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston...
Why Might Night-Shift Workers Have a Higher Risk of Developing Cancer?
New clues as to why night-shift workers are at an increased risk of developing certain types of cancer were uncovered in a new study published by Koritala et al in the Journal of Pineal Research. The study involved a controlled laboratory experiment that used healthy volunteers who were on...
Meta-analysis of Intermediate Clinical Endpoints as Surrogates for Overall Survival in Localized Prostate Cancer
In a meta-analysis reported in The Lancet Oncology, Gharzai et al found that commonly used intermediate clinical endpoints in clinical trials in localized prostate cancer do not correlate well with overall survival, apart from metastasis-free survival—supporting the establishment of metastasis-free ...
Immunotherapy for Advanced Kidney Cancer: Effect of Body Mass Index
In a study reported in a research letter in JAMA Oncology, Lalani et al found that higher body mass index (BMI) was associated with better overall survival among patients with metastatic renal cell carcinoma receiving anti–PD-1/PD-L1–based immune checkpoint inhibitor treatment. No association of...
Weight Gain in Childhood Brain Tumor Survivors and Potential Association With Hypothalamic-Pituitary Dysfunction
In a Dutch study reported in the Journal of Clinical Oncology, van Schaik et al found that significant weight gain and being overweight and/or obese are common in childhood brain tumor survivors and may be associated with hypothalamic-pituitary dysfunction. Study Details The study involved data...
Responses to Conjugate Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia
In an Italian study reported in Leukemia, Mauro et al found that only a small minority of patients with chronic lymphocytic leukemia (CLL) developed an adequate immune response to pneumococcal vaccination, with response being more likely in patients who were younger, had previously untreated and...
Effect of Risk-Adapted Therapy on Long-Term Morbidity in Pediatric Patients With Hodgkin Lymphoma
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Kevin C. Oeffinger, MD, and colleagues found that adoption of risk-adapted therapy in the 1990s was associated with reduced risk of serious chronic health conditions in pediatric Hodgkin lymphoma...
New Study Finds Muscle Mass and Density Are Correlated With Survival and Outcomes in Patients With Advanced Cancer
New research published by van Seventer et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that muscle mass was correlated with survival, while muscle radiodensity was associated with symptom burden, health-care use, and survival in patients with advanced cancer undergoing ...
FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
On March 10, the U.S. Food and Drug Administration (FDA) approved tivozanib (Fotivda), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. TIVO-3 Efficacy was evaluated in TIVO-3 (ClinicalTrials.gov...
Neoadjuvant Atezolizumab in Lung Cancer: LCMC3 Trial Meets Primary Endpoint
Neoadjuvant treatment with single-agent atezolizumab in patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and a pathologic complete response rate of 7%, in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study.1 The findings were...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess Margaret...
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...
Study Finds More Than Half of Cancer Survivors Have Underlying Medical Conditions Associated With Developing Severe COVID-19
A new study found that more than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness.1 The report, appearing in JNCI: The Journal of the National Cancer Institute, suggests that the prevalence of...
Fallout From COVID-19: Decline in Cancer Screening and Increase in Cancer-Related Deaths
Various studies at institutions in the United States and abroad have shown a substantial decline in cancer screening rates during the COVID-19 pandemic, suggesting that fewer cancers will be detected by screening and when they do manifest, they will be at more advanced stages. Indeed,...
Expert Point of View: Rina Hui, MBBS, PhD, and Melina Marmarelis, MD
“It has been a long time coming to see a positive randomized phase III study with a checkpoint inhibitor in relapsed mesothelioma,” said the study’s invited discussant, Rina Hui, MBBS, PhD, Clinical Professor of Medicine, Crown Princess Mary Cancer Centre, Westmead Hospital, University of Sydney,...
CONFIRM Trial Reports Improvement in Survival With Nivolumab in Relapsed Malignant Mesothelioma
For the first time, a treatment has been shown to improve overall survival in heavily pretreated patients with relapsed malignant mesothelioma. In the phase III CONFIRM trial, single-agent nivolumab led to a significant improvement in both overall and progression-free survival, according to...
Once-Weekly Selinexor Plus Bortezomib/Dexamethasone vs Twice-Weekly Bortezomib/Dexamethasone in Multiple Myeloma
As reported in The Lancet by Sebastian Grosicki, MD, of the Medical University of Silesia, Katowice, Poland, and colleagues, the phase III BOSTON trial has shown significantly prolonged progression-free survival with once-weekly selinexor plus bortezomib/dexamethasone vs twice-weekly...
Studies Provide Guidance on the Use of Blinatumomab in Pediatric Acute Lymphoblastic Leukemia
Monotherapy with blinatumomab as consolidation therapy before allogeneic stem cell transplant appears to be the optimal treatment for children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (ALL), according to an international phase III trial that compared this approach...
Crizotinib for Children and Young Adults With Relapsed or Refractory Systemic ALK-Positive Anaplastic Large Cell Lymphoma
On January 14, 2021, crizotinib was approved for treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.1,2 The safety and efficacy of crizotinib have not been established in older...
Tepotinib for Metastatic NSCLC With MET Exon 14–Skipping Alterations
On February 3, 2021, tepotinib was granted accelerated approval for treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14–skipping alterations.1,2 Supporting Efficacy Data Approval was supported by findings from the...
Overcoming Gender Disparity in Evaluating Sexual Health Following a Cancer Diagnosis
The results from a recent study showcase the disturbing prevalence of sexual dysfunction as a treatment side effect of cancer and gender disparity in how the problem is addressed by physicians.1 The study, conducted by James Taylor, MD, MPH, Chief Resident in the Department of Radiation Oncology at ...
Novel Therapies Under Study in Chronic Myeloid Leukemia
“There is progress whether ye are going forward or backward! The thing is to move.” —Edgar Cayce To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are a few abstracts selected from the meeting...
The Emerging Role of Exercise in Cancer Prevention and Treatment
The holistic benefits derived from exercise in preventing and ameliorating chronic health conditions such as cardiovascular disease and diabetes are well documented. However, less is known about the salutary effects exercise may have across the cancer setting, especially during treatment....
Updated Analysis of Outcomes With Entrectinib for Advanced ROS1 Fusion–Positive NSCLC
As reported in the Journal of Clinical Oncology by Rafal Dziadziuszko, MD, and colleagues, an updated integrated analysis of three phase I or II trials of entrectinib in patients with advanced ROS1-positive non–small cell lung cancer (NSCLC) indicated that treatment continues to be associated with...
Outcomes With Internal Mammary and Medial Supraclavicular Nodal Irradiation in Stage I to III Breast Cancer
As reported in The Lancet Oncology by Philip M. Poortmans, PhD, Department of Radiation Oncology of the Iridium Netwerk and the Faculty of Medicine and Health Sciences, University of Antwerp, and colleagues, 15-year outcomes of the phase III EORTC 22922/10925 trial show continued reduction in...
Complete Mesocolic Excision vs D2 Dissection in Patients Undergoing Laparoscopic Colectomy for Right-Sided Colon Cancer
In an analysis of early safety outcomes in a Chinese phase III trial (RELARC) reported in The Lancet Oncology, Xu et al found similar surgical complication rates with complete mesocolic excision vs D2 dissection in patients undergoing laparoscopic colectomy for right-sided colon cancer. The...
Expert Point of View: John C. Krauss, MD
Invited discussant John C. Krauss, MD, Medical Oncology Director of the Multidisciplinary Colorectal Cancer Clinic, Rogel Cancer Center of the University of Michigan, Ann Arbor, said he was impressed by the “rapidity with which the NRG-GI002 trial accrued,” which was about 10 months.1 “Equally...
Study Reports Little Benefit to Adding Pembrolizumab to Neoadjuvant Therapy for Locally Advanced Rectal Cancer
The addition of pembrolizumab to neoadjuvant chemotherapy and radiotherapy (ie, total neoadjuvant therapy) failed to improve a rectal cancer–specific surrogate for survival in patients with locally advanced disease in the phase II NRG-GI002 trial.1 As reported at the 2021 Gastrointestinal Cancers...
Childhood Cancer Survivors and Health-Care Providers Satisfied With Video Visits During the COVID-19 Pandemic
When the COVID-19 pandemic limited in-person medical checkups last year, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center offered video visits for the first time for long-term follow-up appointments for childhood cancer survivors. Due to the pandemic, virtual visits were adopted...
FDA Pipeline: Designations in Ovarian, Head/Neck, and Thyroid Cancers
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a novel immunotherapy for the treatment of ovarian cancer as well as Breakthrough Therapy designation to treatments for HRAS-mutant head and neck squamous cell carcinoma and previously treated thyroid cancer....
Increase in Diagnosis of Node-Positive and Stage III Breast Cancer After Screening Interruption Due to the COVID-19 Pandemic
A new report from Italy published by Toss et al in ESMO Open noted an increase in diagnoses of node-positive and stage III breast cancer after a 2-month interruption in breast cancer screening due to the COVID-19 pandemic. These findings support recommendations for a quick restoration of breast...
Idecabtagene Vicleucel for Heavily Pretreated Patients With Relapsed or Refractory Multiple Myeloma
In the pivotal phase II KarMMa study reported in The New England Journal of Medicine, Nikhil C. Munshi, MD, and colleagues found that the B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel produced high response rates in patients with...
Role of Collagen in Pancreatic Cancer Development
Type I collagen produced by cancer-associated fibroblasts may not promote cancer development, but instead, may play a protective role in controlling pancreatic cancer progression. This new understanding supports novel therapeutic approaches that bolster collagen rather than suppress it, according...
Study Finds Cancer Survivors With Poor Ambulatory Function May Be at an Increased Risk of Death
A study by Salerno et al published in Cancer Epidemiology, Biomarkers & Prevention investigating the association of a cancer diagnosis and poor ambulatory function of survivors and subsequent mortality has found that cancer survivors with poor ambulatory function had a two to three times...
Effect of Clinical Breast Examination Screening on Stage at Diagnosis and Breast Cancer Mortality
In an Indian study reported in the British Medical Journal, Mittra et al found that breast cancer screening with clinical breast examination vs active surveillance resulted in younger age and significant downstaging of disease at diagnosis of breast cancer, a significant reduction in breast cancer...
Mental Health Service Use Among Testicular Cancer Survivors
In a Canadian population-based cohort study reported in the Journal of Clinical Oncology, Raphael et al found that survivors of testicular cancer were more likely to use mental health services in both the short and long term following treatment compared with the general population. Study Details...
FDA Approves Lorlatinib for Metastatic ALK-Positive NSCLC
On March 3, the U.S. Food and Drug Administration (FDA) granted regular approval to lorlatinib (Lorbrena) for patients with metastatic non–small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. The FDA also approved the...
Study Finds Missing Annual Mammogram Increases Risk of Death From Breast Cancer
Regular mammography screening substantially reduces the risk of dying from breast cancer, according to a large study of over half a million women published by Stephen W. Duffy, MSc, and colleagues in the journal Radiology. Researchers said women who skipped even one scheduled mammography screening...
Five-Year Outcomes With Tisagenlecleucel in Patients With Relapsed or Refractory B-Cell Lymphomas
As reported in a letter to the editor in The New England Journal of Medicine by Elise A. Chong, MD, and colleagues, long-term follow-up of a single-center trial of tisagenlecleucel showed maintained responses in a high proportion of patients with relapsed or refractory diffuse large B-cell lymphoma ...
Study Examines Extrapleural Pneumonectomy After IMRT for Malignant Pleural Mesothelioma
In a Canadian single-center phase II feasibility study reported in The Lancet Oncology, Cho et al found that a treatment protocol (surgery for mesothelioma after radiotherapy, also known as SMART) consisting of hemithoracic intensity-modulated radiotherapy (IMRT) followed by extrapleural...
Anti-CD20 Monoclonal Antibodies and Risk of Severe COVID-19 Infection and Death in Patients With Lymphoma
Patients with lymphoma hospitalized for severe COVID-19 infection were at higher risk for prolonged hospital stay and death if they were treated with B-cell–depleting therapies (eg, rituximab, obinutuzumab) within the previous 12 months. The risk of persistent COVID-19 infection was also higher in...
ASCO’s Road to Recovery Report Outlines Lessons Learned From the COVID-19 Pandemic to Improve Oncology Care
In 2020, ASCO established the Steering Group on Cancer Care Delivery and Research in a Post-Pandemic Environment to evaluate the changes made in oncology care delivery, clinical research, and regulatory oversight in response to the COVID-19 pandemic as well as to make recommendations on how to...
SWOG 1500: Cabozantinib, Crizotinib, or Savolitinib vs Sunitinib in Metastatic Papillary Renal Cell Carcinoma
In the phase II SWOG 1500 study reported in The Lancet, Pal et al found that among three comparator MET kinase inhibitors, cabozantinib prolonged progression-free survival vs sunitinib in metastatic papillary renal cell carcinoma. Study Details In the open-label trial, 147 eligible patients from...
CLEAR Trial: Is Lenvatinib Plus Pembrolizumab the Best First-Line Immunotherapy Doublet in Metastatic Renal Cell Carcinoma?
At the 2021 Genitourinary Cancers Symposium, Motzer et al presented the clinical results of the CLEAR trial, adding a novel regimen, lenvatinib plus pembrolizu-mab, to the growing armamentarium of first-line treatments for patients with metastatic clear cell renal cell carcinoma (RCC). The...
FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
On February 26, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (Pepaxto) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is...
Enfortumab Vedotin-ejfv in Previously Treated Advanced Urothelial Carcinoma
As reported in The New England Journal of Medicine by Powles et al, a prespecified interim analysis of the phase III EV-301 trial has shown improved overall survival with enfortumab vedotin-ejfv vs investigator choice of chemotherapy in patients with previously treated advanced urothelial...
